Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Pharma
Novartis' Fabhalta nod in C3G leaves room for rival Apellis
Analysts spotted several shortfalls in Fabhalta's first-in-disease FDA approval, leaving the door open for rival Apellis.
Angus Liu
Mar 21, 2025 10:37am
Vertex centers National Kidney Month awareness on patient story
Mar 7, 2025 9:15am
Novartis, Apellis roll out rival datasets in rare kidney disease
Oct 28, 2024 10:03am
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Oct 25, 2024 8:43am
Roche's Gazyva chases new kidney disease use with phase 3 win
Sep 26, 2024 11:30am
Despite trial scare, Travere's IgAN drug wins full FDA approval
Sep 5, 2024 5:40pm
